Affymax (AFFY) versus Aevi Genomic Medicine (GNMX) Critical Survey

Affymax (OTCMKTS: AFFY) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Affymax and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Affymax N/A N/A N/A
Aevi Genomic Medicine N/A -125.94% -106.93%

Analyst Recommendations

This is a summary of recent ratings for Affymax and Aevi Genomic Medicine, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affymax 0 0 0 0 N/A
Aevi Genomic Medicine 0 1 1 0 2.50

Aevi Genomic Medicine has a consensus price target of $4.25, indicating a potential upside of 137.43%. Given Aevi Genomic Medicine’s higher probable upside, analysts plainly believe Aevi Genomic Medicine is more favorable than Affymax.

Risk and Volatility

Affymax has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Institutional and Insider Ownership

20.8% of Aevi Genomic Medicine shares are held by institutional investors. 1.6% of Affymax shares are held by company insiders. Comparatively, 15.2% of Aevi Genomic Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Affymax and Aevi Genomic Medicine’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Affymax $41,999.00 29.87 -$47.65 million N/A N/A
Aevi Genomic Medicine N/A N/A -$37.80 million ($1.02) -1.75

Aevi Genomic Medicine has higher revenue, but lower earnings than Affymax.

Summary

Aevi Genomic Medicine beats Affymax on 5 of the 9 factors compared between the two stocks.

Affymax Company Profile

Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn?s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Affymax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.